Introducing the world's first dual-targeted peptide new drug MT1013 EVEREST MED(01952) to strengthen the layout of the field of nephrology.

On February 5th, Hong Kong innovative pharmaceutical company EVEREST MED (01952) announced that it has signed an exclusive commercial license agreement with Macuot for the global first-in-class dual-target peptide new drug MT1013 in China and the Asia-Pacific region (excluding Japan). This collaboration marks the upgrade of EVEREST MED's renal strategic focus from a single disease area to a systematic and platform-oriented development stage. MT1013 will synergize with EVEREST MED's existing renal pipeline to strengthen product layout, consolidate the company's leading position in the Asian kidney and autoimmune disease field, and expand product coverage from IgA nephropathy to a broader range of chronic kidney disease areas. Under the agreement, EVEREST MED will pay Macuot a first payment of RMB 200 million, as well as potential regulatory and commercial milestone payments not exceeding RMB 1.04 billion. Phase III clinical trials in China are ongoing, and related clinical development costs will be borne by Macuot. By introducing MT1013 as a late-stage innovative asset, EVEREST MED will further enrich its renal pipeline portfolio, building a sustainable pipeline system that combines short-term returns, medium-term growth, and long-term potential, to establish a solid foundation for the company's long-term and steady development. Regarding this collaboration, Chairman of EVEREST MED's Board of Directors, Wu Yifang, stated: "With the continuous increase in the global population of chronic kidney disease patients, there remains a significant unmet clinical need for secondary hyperparathyroidism. As a late-stage clinical innovative asset with a dual-target mechanism, MT1013 is expected to provide a new treatment option for SHPT patients. This collaboration is an important strategic move for the company to enhance its innovative pipeline and expand the boundaries of kidney treatment." Dr. Wang Bing, founder and chairman of Macuot, said: "EVEREST MED has profound market accumulation and a mature commercial system in the field of kidney disease, making it an ideal partner to benefit MT1013 for Chinese and global patients. The unique dual-target mechanism of MT1013 is expected to bring breakthroughs and more benefits to SHPT treatment." It is understood that secondary hyperparathyroidism (SHPT) is one of the most common serious complications in patients with chronic kidney disease (CKD), leading to a series of pathological changes such as calcium and phosphorus metabolism disorders, increased parathyroid hormone levels, bone disease, vascular calcification, significantly increasing the risk of fractures, cardiovascular events, and death, and is a key factor affecting the prognosis of CKD patients. MT1013 is a globally first-in-class dual-target peptide new drug independently developed by Macuot, scheduled to be featured in the "Late-Breaking" session at the American Society of Nephrology (ASN) Annual Meeting in 2025. MT1013 innovatively combines the "calcium-sensing receptor (CaSR) + osteoglycin (OGP) mimic" dual-action mechanism, addressing the imbalance of PTH, calcium, and phosphorus metabolism. This new design allows it to control the condition from the source in treating SHPT and related skeletal metabolic diseases for the first time, and actively promote bone formation and repair by directly activating the bone formation pathway, achieving a therapeutic innovation upgrade from "indirect bone resorption inhibition" to "active bone formation promotion." In addition, MT1013 is also planned to be expanded to additional indications including chronic kidney disease mineral and bone metabolism disorders (CKD-MBD) with osteoporosis and SHPT not undergoing dialysis. Currently, the global population of chronic kidney disease (CKD) patients has increased from 9.052 billion in 2019 to 10.655 billion in 2024, expected to exceed 1.2 billion in 2030 and over 1.5 billion in 2035; SHPT patients are expected to reach 189 million in 2030 and 221.7 million in 2035. According to Macuot's prospectus, MT1013 is expected to be commercialized in early 2028, while the market size of drugs for secondary hyperparathyroidism (SHPT) in China is expected to reach RMB 5.5 billion in 2030 and RMB 14.1 billion in 2035, with a compound annual growth rate of 20.5%, coupled with the continuously growing demand from patients, MT1013 has a broad market outlook. MT1013 has completed key Phase II clinical trials, with data showing that it demonstrates strong and lasting iPTH suppression in SHPT patients undergoing maintenance hemodialysis, and achieves comprehensive management advantages compared with etelcalcetide, validating its unique dual mechanism in comprehensive management and improving bone health potential clinical benefits for SHPT patients.